OmniAb, Inc.

OmniAb, Inc. is a biotechnology platform company specializing in antibody discovery, headquartered in Emeryville, California. The company's mission is to enable the rapid development of innovative therapeutics by advancing drug discovery technologies.

At the core of OmniAb's offerings is its proprietary OmniAb platform, which leverages the "Biological Intelligence™" of genetically engineered transgenic animals, including OmniRat®, OmniChicken®, and OmniMouse®, to generate diverse antibody repertoires with human sequences. The company licenses these cutting-edge discovery research technologies and provides related scientific services to pharmaceutical and biotechnology companies, as well as academic institutions, to facilitate the discovery of next-generation therapeutics. Key technologies also include OmniFlic® and OmniClic® for bispecific antibodies, OmniTaur™ for cow-inspired antibodies, OmniUltra™ for ultralong CDRH3 domains and picobodies, OmnidAb® for single domain antibodies, xPloration® for high-throughput single B-cell screening, and OmniDeep™ for in silico, AI, and machine learning tools.

OmniAb became an independent publicly traded company in November 2022, following a spin-off from Ligand Pharmaceuticals Incorporated and a business combination. Led by CEO Matt Foehr, the company reported strong financial results for Q1 2026, with a significant revenue surge, and subsequently raised its full-year 2026 guidance. OmniAb positions itself as a critical enabler in the antibody discovery space, collaborating with over 100 active partners, including some of the world's largest pharmaceutical companies, through a business model that includes upfront fees, service revenue, milestones, and royalties.